

# Jacques Genest jr

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8257850/jacques-genest-jr-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97  
papers

13,726  
citations

35  
h-index

110  
g-index

110  
ext. papers

17,242  
ext. citations

6.9  
avg, IF

5.99  
L-index

#	Paper	IF	Citations
97	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. <i>Lancet, The</i> , <b>2022</b> ,	4.0	4
96	Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux.. <i>Communications Biology</i> , <b>2022</b> , 5, 132	6.7	0
95	New Strategies to Promote Macrophage Cholesterol Efflux.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 795868	5.4	1
94	Influence of the LDL-receptor genotype on statin response in heterozygous familial hypercholesterolemia: insights from the Canadian FH Registry. <i>Canadian Journal of Cardiology</i> , <b>2021</b> ,	3.8	1
93	Identification of Docetaxel as a Potential Drug to Promote HDL Biogenesis. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 679456	5.6	3
92	Sex Differences in the Presentation, Treatment, and Outcome of Patients With Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e019286	6	1
91	Dj1 deficiency protects against atherosclerosis with anti-inflammatory response in macrophages. <i>Scientific Reports</i> , <b>2021</b> , 11, 4723	4.9	1
90	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , <b>2021</b> , 37, 1129-1150	3.8	62
89	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , <b>2021</b> , 398, 1713-1725	4.0	14
88	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2021</b> , 41, 2632-2640	9.4	6
87	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. <i>Circulation</i> , <b>2020</b> , 141, 1742-1759	16.7	117
86	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. <i>Atherosclerosis</i> , <b>2020</b> , 311, 13-19	3.1	14
85	Evidence for improved survival with treatment of homozygous familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , <b>2020</b> , 31, 176-181	4.4	6
84	Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience. <i>Atherosclerosis</i> , <b>2020</b> , 310, 54-63	3.1	4
83	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. <i>CJC Open</i> , <b>2019</b> , 1, 190-197	2	2
82	HDL cholesterol and ASCVD risk stratification: A debate. <i>Atherosclerosis</i> , <b>2019</b> , 283, 7-12	3.1	27
81	ABCA1 Agonist Mimetic Peptide CS-6253 Induces Microparticles Release From Different Cell Types by ABCA1-Efflux-Dependent Mechanism. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 770-781	3.8	11

80	Risk of Ischemic Stroke and Peripheral Arterial Disease in Heterozygous Familial Hypercholesterolemia: A Meta-Analysis. <i>Angiology</i> , <b>2019</b> , 70, 726-736	2.1	7
79	Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 1262-1270	3.9	16
78	The Lifelong Burden of Homozygous Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 1419.e1-1419.e4	3.8	2
77	Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , <b>2019</b> , 13, 15-30	4.9	28
76	Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , <b>2019</b> , 13, 123-128	4.9	11
75	Severe xanthomatosis in heterozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 872-877	4.9	15
74	Familial hypercholesterolemia: experience from the French-Canadian population. <i>Current Opinion in Lipidology</i> , <b>2018</b> , 29, 59-64	4.4	17
73	Desmocollin 1 is abundantly expressed in atherosclerosis and impairs high-density lipoprotein biogenesis. <i>European Heart Journal</i> , <b>2018</b> , 39, 1194-1202	9.5	15
72	Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 1027-1038	4.9	9
71	Anxiety, depression, and health-related quality of life in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. <i>Journal of Psychosomatic Research</i> , <b>2018</b> , 109, 32-43	4.1	8
70	HDLs and the pathogenesis of atherosclerosis. <i>Current Opinion in Cardiology</i> , <b>2018</b> , 33, 311-316	2.1	12
69	Pathological significance of lipoprotein(a) in aortic valve stenosis. <i>Atherosclerosis</i> , <b>2018</b> , 272, 168-174	3.1	14
68	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 355-362	5.5	32
67	Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. <i>Atherosclerosis</i> , <b>2018</b> , 276, 98-108	3.1	172
66	Membrane microdomains and the regulation of HDL biogenesis. <i>Current Opinion in Lipidology</i> , <b>2018</b> , 29, 36-41	4.4	8
65	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet, The</i> , <b>2018</b> , 391, 319-328	4.0	430
64	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1553-1563	3.8	58
63	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , <b>2018</b> , 277, 234-255	3.1	93

62	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. <i>Atherosclerosis</i> , <b>2018</b> , 277, 419-424	3.1	10
61	Simplified Canadian Definition for Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1210-1214	3.8	36
60	Estrogen-associated severe hypertriglyceridemia with pancreatitis. <i>Journal of Clinical Lipidology</i> , <b>2017</b> , 11, 297-300	4.9	14
59	ATP binding cassette A1 (ABCA1) mediates microparticle formation during high-density lipoprotein (HDL) biogenesis. <i>Atherosclerosis</i> , <b>2017</b> , 257, 90-99	3.1	40
58	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. <i>Circulation</i> , <b>2017</b> , 135, 1819-1831	16.7	52
57	Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 658-665	3.8	12
56	Effect of interleukin-1 $\beta$ inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2017</b> , 390, 1833-1842	4.0	634
55	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1119-1131	59.2	3877
54	Lipoprotein(a) Induces Human Aortic Valve Interstitial Cell Calcification. <i>JACC Basic To Translational Science</i> , <b>2017</b> , 2, 358-371	8.7	34
53	Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. <i>BMJ Open</i> , <b>2017</b> , 7, e016461	3	160
52	Novel Approaches for HDL-Directed Therapies. <i>Current Atherosclerosis Reports</i> , <b>2017</b> , 19, 55	6	6
51	High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 325-333	3.8	30
50	The Essential Role of Primary Caregiver in Early Detection of Familial Hypercholesterolemia and Cardiovascular Prevention. <i>Current Pediatric Reviews</i> , <b>2017</b> , 13, 260-264	2.8	
49	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1263-1282	3.8	543
48	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2016</b> , 4, 850-61	18.1	215
47	Reducing Vascular Calcification by Anti-IL-1 $\beta$ Monoclonal Antibody in a Mouse Model of Familial Hypercholesterolemia. <i>Angiology</i> , <b>2016</b> , 67, 157-67	2.1	31
46	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. <i>Clinical Chemistry</i> , <b>2016</b> , 62, 428-35	5.5	15
45	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, S35-65	3.8	138

44	Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1552-1560	3.8	10
43	High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. <i>BBA Clinical</i> , <b>2015</b> , 3, 175-88		96
42	Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of pre $\beta$ HDL In Vitro. <i>PLoS ONE</i> , <b>2015</b> , 10, e0131997	3.7	35
41	HDL-Mediated Cellular Cholesterol Efflux Assay Method. <i>Annals of Clinical and Laboratory Science</i> , <b>2015</b> , 45, 659-68	0.9	11
40	High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 249-55	3	47
39	Long-term effects of 4 popular diets on weight loss and cardiovascular risk factors: a systematic review of randomized controlled trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2014</b> , 7, 815-27 <sup>5.8</sup>		45
38	Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia. <i>Clinical Chemistry</i> , <b>2014</b> , 60, 1380-9	5.5	27
37	Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2014</b> , 1842, 1498-512	5	22
36	The WWOX gene modulates high-density lipoprotein and lipid metabolism. <i>Circulation: Cardiovascular Genetics</i> , <b>2014</b> , 7, 491-504		26
35	Apolipoprotein A-I truncations in Chagas disease are caused by cruzipain, the major cysteine protease of <i>Trypanosoma cruzi</i> . <i>American Journal of Pathology</i> , <b>2014</b> , 184, 976-984	5.8	9
34	Severe hyperhomocysteinemia due to cystathionine $\beta$ -synthase deficiency, and Factor V Leiden mutation in a patient with recurrent venous thrombosis. <i>Thrombosis Journal</i> , <b>2014</b> , 12, 30	5.6	4
33	Canadian Cardiovascular Society position statement on familial hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 1471-81	3.8	71
32	Treatment options for low high-density lipoproteins. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2014</b> , 21, 134-9	4	10
31	Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease. <i>Peptides</i> , <b>2014</b> , 55, 151-7	3.8	12
30	Aortic calcification: Novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptor. <i>Atherosclerosis</i> , <b>2013</b> , 226, 9-15	3.1	119
29	APOE p.Leu167del mutation in familial hypercholesterolemia. <i>Atherosclerosis</i> , <b>2013</b> , 231, 218-22	3.1	67
28	HDL, Atherosclerosis, and Emerging Therapies. <i>Cholesterol</i> , <b>2013</b> , 2013, 891403		59
27	Genetics of cholesterol efflux. <i>Current Atherosclerosis Reports</i> , <b>2012</b> , 14, 235-46	6	12

26	The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. <i>Atherosclerosis</i> , <b>2011</b> , 219, 455-62	3.1	50
25	Membrane microdomains modulate oligomeric ABCA1 function: impact on apoA1-mediated lipid removal and phosphatidylcholine biosynthesis. <i>Journal of Lipid Research</i> , <b>2011</b> , 52, 2043-55	6.3	23
24	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. <i>Lancet, The</i> , <b>2010</b> , 376, 333-9	40	178
23	C-reactive protein: risk factor, biomarker and/or therapeutic target?. <i>Canadian Journal of Cardiology</i> , <b>2010</b> , 26 Suppl A, 41A-44A	3.8	72
22	Aortic calcifications in familial hypercholesterolemia: potential role of the low-density lipoprotein receptor gene. <i>American Heart Journal</i> , <b>2009</b> , 157, 170-6	4.9	26
21	Approach to the diagnosis and management of lipoprotein disorders. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2009</b> , 16, 132-40	4	17
20	Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 2195-207	59.2	4661
19	Disorders of high-density lipoprotein biogenesis. <i>Annals of Medicine</i> , <b>2008</b> , 40, 39-47	1.5	1
18	Quantitative analysis of ABCA1-dependent compartmentalization and trafficking of apolipoprotein A-I: implications for determining cellular kinetics of nascent high density lipoprotein biogenesis. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 11164-75	5.4	46
17	Abstract 1696: Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early (phase I) Human Trials. <i>Circulation</i> , <b>2008</b> , 118,	16.7	2
16	Genetics of High-Density Lipoproteins <b>2007</b> , 465-490		
15	Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. <i>Canadian Journal of Cardiology</i> , <b>2006</b> , 22, 863-8	3.8	13
14	The analysis by Manuel and colleagues creates controversy with headlines, not data. <i>Cmaj</i> , <b>2005</b> , 172, 1033-4; discussion 1037	3.5	3
13	Biogenesis and speciation of nascent apoA-I-containing particles in various cell lines. <i>Journal of Lipid Research</i> , <b>2005</b> , 46, 1668-77	6.3	62
12	Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 848-53	3	42
11	High-density lipoproteins: multifunctional vanguards of the cardiovascular system. <i>Expert Review of Cardiovascular Therapy</i> , <b>2004</b> , 2, 417-30	2.5	13
10	Preventive cardiology: move over low density lipoprotein cholesterol, hello C-reactive protein?. <i>Canadian Journal of Cardiology</i> , <b>2004</b> , 20 Suppl B, 89B-92B	3.8	
9	Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. <i>FASEB Journal</i> , <b>2003</b> , 17, 512-4	0.9	130

8	Prevention of cardiovascular ischemic events: high-risk and secondary prevention. <i>Circulation</i> , <b>2003</b> , 107, 2059-65	16.7	40
7	Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. <i>Cmaj</i> , <b>2003</b> , 169, 921-4	3.5	86
6	Genetics and prevention: a new look at high-density lipoprotein cholesterol. <i>Cardiology in Review</i> , <b>2002</b> , 10, 61-71	3.2	13
5	Novel insights on high-density lipoprotein in coronary heart disease. <i>International Journal of Clinical Practice, Supplement</i> , <b>2002</b> , 17-22		
4	Plasma homocysteine concentration in children with chronic renal failure. <i>Pediatric Nephrology</i> , <b>2001</b> , 16, 805-11	3.2	43
3	Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. <i>Circulation</i> , <b>2001</b> , 103, 1198-205	16.7	262
2	High-density lipoproteins and endothelial function. <i>Circulation</i> , <b>2001</b> , 104, 1978-83	16.7	158
1	Familial hypercholesterolemia. Acceptor splice site (G-->C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R(Honduras-1) [LDL-R1061(-1) G-->C]. <i>Atherosclerosis</i> , <b>1999</b> , 146, 125-31	3.1	22